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Available online 19 November 2015The p38 MAP kinase is a promising cancer drug target but its therapeutic effect is not fully understood. Here we
report that the response of colorectal cancer (CRC) to p38 inhibitors (p38i) is highly variable: while p38i induces
regression of one subgroup of CRCs, it stimulates growth of another subgroup. We further show that PP2AC is
differentially expressed in the two different CRC subgroups, which determines the programing of p38-TSC-
mTORC1 signaling through differential TSC2 phosphorylation at S664, 1254 and 1798, and the antitumor activity
by p38i. Remarkably, modulation of PP2AC level is sufﬁcient to reprogram p38-to-mTORC1 signaling and
antitumor response. PP2AC expression accurately predicts therapeutic response to p38i in several CRCmodels, in-
cluding a large cohort of patient-derived xenografts (PDXs). Moreover, we demonstrate that combination of p38
and mTOR kinase inhibitors effectively overcomes resistance to either inhibitor in single agent therapy. These
results demonstrate that alternative routing of signal transduction underlies differential response to p38 and
mTOR targeted therapies. The biomarker-guided therapeutic strategies described herein provide a compelling rea-
son for testing in metastatic CRC patients who suffer very poor prognosis due to lack of efﬁcacious drug therapies.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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PDX1. Introduction
Colorectal cancer (CRC) is a major global health concern, which
accounts for 1,400,000 new cancer cases and nearly 700,000 deaths in
2012. It is prevalent in developed countries but has seen rapid rise in
developing countries. Early stage CRC can be treated with combination
of surgery and chemotherapy, which has good progression-free and
overall survival rates. However, formetastatic CRC, the ﬁve-year survival
rate is only 11% according to American Cancer Society. Standard systemic
treatment is chemotherapy with cytotoxic drugs ﬂuorouracil or capecit-
abine (Segal and Saltz, 2009). In recent years, targeted agents VEGF and
EGFR inhibitors have been introduced (Misale et al., 2012). However,
the overall death rate in metastatic CRC remains high because EGFR
therapeutic antibodies Cetuximab and Panitumumab only beneﬁt
approximately 25% metastatic CRC patients (Misale et al., 2014). Theent, Shanghai Ninth People's
, Shanghai 201900, China.
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. This is an open access article underremainder is refractory to EGFR targeted therapy mainly due to muta-
tions in K-RAS, and in some cases B-RAF or PIK3CA (Misale et al.,
2014). Because these patients suffer very poor prognosis, new systemic
therapy is urgently needed to improve survival.
The p38 mitogen-activated protein kinases (MAPK) are key regula-
tors of cellular responses to stress stimuli such as heat and osmotic
shock, UV irradiation and inﬂammatory cytokines (Ashwell, 2006;
Nebreda and Porras, 2000). There are four members in this MAPK sub-
family: p38α, p38β, p38γ and p38δ. While p38α is ubiquitous, expres-
sion of other p38 isoforms ismore restricted. p38MAPK phosphorylates
a myriad of substrates including transcription factors and kinases that
mediate responses in inﬂammation, differentiation, cell cycle, apoptosis
and cytokine production. Althoughmuch attention has been focused on
p38 in inﬂammation, increasing evidence indicates that p38 is impor-
tant for a number of other diseases including cancer (Han and Sun,
2007; Wagner and Nebreda, 2009). Elevated p38α activity occurs in
CRC, mammary carcinomas, follicular lymphoma, glioma, head and
neck squamous cell carcinomas, lung cancer, and thyroid cancer (Koul
et al., 2013). In CRC, p38α and p38β (referred to as p38 hereafter) are
especially essential for cancer cell proliferation and survival (Comes
et al., 2007; Gupta et al., 2014). Genetic ablation or chemical inhibitionthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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speciﬁc manner. In addition, targeting p38α and p38β sensitizes CRC
cells to 5-ﬂuorouracil and overcomes irinotecan resistance (de la
Cruz-Morcillo et al., 2012; Paillas et al., 2011).
p38 is a major therapeutic target for inﬂammatory diseases. Many
selective p38α and p38β inhibitors (p38i) have been developed
(Kumar et al., 2003). Although earlier trials with rheumatoid arthritis
have not demonstrated superiority for this class of drugs over the stan-
dard care steroid treatment, promising clinical results have been obtain-
ed for acute coronary syndrome, atherosclerosis and chronic obstructive
pulmonary disease (COPD). For example, a recent phase 2 clinical trial
on acute coronary syndromes with an oral p38 inhibitor showed that
the drug has achieved favorable clinical endpoints (Newby et al.,
2014), which led to initiation of a large phase 3 trial involving 25,000
patients. As a result of a decade's effort by the pharmaceutical and bio-
tech industry in this therapeutic space, a large collection of high quality
p38is have been tested inhumans and shown tohave desirable pharma-
cological and toxicological proﬁles.
As p38 is essential for many human malignancies including CRC,
some p38is have been tested in early stage human cancer clinical trials
(https://clinicaltrials.gov). To date, however, positive results have not
been reported. It has become clear that due to inter-patient and intra-
patient heterogeneous nature of human tumors, only a subgroup(s) of
any given cancer type would likely respond favorably to a particular
p38i-targeted therapy. Clinical success of targeted therapies, as illustrat-
ed by EGFR inhibitors erlotinib and geﬁtinib, hinges upon a comprehen-
sive understanding of the anticancermechanism and reliable predictive
biomarkers to identify the responders (Zhang et al., 2009). Currently,
basic mechanistic insight into the sensitivity and resistance to p38is in
cancer is needed. To this end, we investigated how CRCs respond to
p38is. Our results provide insight into the molecular mechanisms
for p38i sensitivity and resistance. More importantly, we identify a
predictive biomarker of response to p38i to guide personalized therapy
in different metastatic CRC subgroups.
2. Results
2.1. Opposing Effect of p38i on the Growth and Survival of Different
Subgroups of CRCs
To evaluate therapeutic beneﬁts of p38i, we examined the anticancer
activity of SB202190, a selective inhibitor for p38α and p38β (Lee et al.,
1994), on a panel of CRC cell lines. SB202190 attenuated growth of a
subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose-
and time-dependent manner (Fig. 1A). SB202190 strongly inhibited
colony formation and anchorage-independent growth (Fig. 1B and
C) and elevated apoptotic cell death (Fig. 1D) in this same subset of
CRC lines. In contrast, SB202190 surprisingly enhanced malignant
growth and survival of another subgroup of CRC cell lines, HCT116,
SW1116 and SW620 (Fig. 1A-D). The same therapeutic response was
validated with xenograft tumors derived from SW480 and RKO, and
HCT116 and SW620 cells (Fig. 1E-H) (No statistically signiﬁcant animal
weight ﬂuctuations were observed in SB202190-treated groups
compared with VC group, data not shown). LY2228820 and BIRB796,
two other selective p38 inhibitors that have been tested in human
clinical trials (Regan et al., 2003; Tate et al., 2013), exhibited similar
therapeutic proﬁles to SB202190 (Supplementary Fig. 1), suggesting
that the differential anti-CRC response was a common property for this
class of p38 inhibitors.
2.2. CRC Subgroups have Opposing mTORC1 Signaling Responses to p38i
p38 has been shown to inhibit serum-stimulated mTORC1 signaling
in immortalized murine embryonic ﬁbroblasts (MEFs) (Li et al., 2003).
To test if mTORC1 is involved in the antitumor response to p38i, we
examined the effect of p38i on mTORC1 signaling in the two subgroupsof CRCs. In RKO, CACO2 and SW480 cells, SB202190 abrogates
phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473),
indicating that p38i selectively blocks mTORC1 signaling (Fig. 2A). In
sharp contrast, SB202190 leads to a robust increase in
phosphorylation of S6K1 and S6 in HCT116, SW1116 and SW620 cells
(Fig. 2A), indicating that blockade of p38 signaling results in mTORC1
activation. Decreased AKT phosphorylation is seen in HCT116,
SW1116 and SW620 cells, which can be explained by activation of the
mTORC1-to-AKT negative feedback loop (Shi et al., 2005; Sun et al.,
2005). The effect of SB202190 on mTORC1 signaling occurred rapidly
and sustainably (Fig. 2B), which was also seen in SB202190-treated xe-
nograft tumors (Fig. 2C-E). In all cases, excellent on-target p38 inhibi-
tion was achieved as indicated by blockage of phosphorylation of MK2
and p27, two established p38 substrates, in both drug-sensitive and -re-
sistant CRC cells or tumors. Finally, LY2228820 and BIRB796 produced
the same results as SB202190 (Fig. 2F). Thus, the differential effect on
mTORC1 signaling is common to distinct p38i. Thus, the opposing ef-
fects of p38i on the two subgroups of CRCs are not due to variable p38
targeting efﬁciency. Instead, they reﬂect distinct intrinsic properties of
individual CRCs.
2.3. p38i Targets Distinct TSC2 Phosphorylation Sites in Different Subgroups
of CRCs
The tumor suppressor Tuberous Sclerosis Complex (TSC), consisting
of TSC1 and TSC2 subunits, negatively regulates mTORC1 signaling
by integrating diverse upstream growth and stress signals through
phosphorylation of TSC2 at distinct sites by upstream kinases (Huang
and Manning, 2008; Tee et al., 2003). In MEFs, SB202190 inhibited
mTORC1 through MK2-dependent phosphorylation of TSC2 at S1254
(Li et al., 2003), and deletion of TSC1 or TSC2 abrogated this mTORC1
inhibition (Fig. 3A). Knockdown of TSC1 or TSC2 in CRC cells abrogated
the negative or positive effect of SB202190 on mTORC1 signaling
(Fig. 3B) or CRC growth (Fig. 3C). These results indicate that TSC is
crucial for the therapeutic response to p38i in CRC.
TSC2 is phosphorylated at S1254, T1462, S664 and S1798 by MK2,
AKT, ERK and RSK, respectively (Inoki et al., 2002; Li et al., 2003; Ma
et al., 2005; Potter et al., 2002). In this role, RSK also serves as a down-
stream effector of ERK. To gain an insight into the differential effects
by p38i, we investigated changes in TSC2 phosphorylation following
SB202190 treatment in different CRC cells. In RKO, SW480 and CACO2
cells, SB202190 blocked MK2-dependent TSC2 phosphorylation at
S1254 (left panel in boxed area, Fig. 3D), without affecting AKT-, ERK-
and RSK-dependent phosphorylation at T1462, S664 and S1798
(Fig. 3D). In contrast, in HCT116, SW1116 and SW620 cells, SB20219 en-
hanced ERK- and RSK-dependent TSC2 phosphorylation at S664 and
S1798 (boxed area in right panel, Fig. 3D), but did not affect AKT- and
MK2-dependent phosphorylations (Fig. 3D).
Consistently, SB202190 results in activation of ERK and RSK kinases
in SW620 and HCT116 cells (Fig. 3E). To verify if ERK is involved, we
treated SW620 and HCT116 cells with the MEK inhibitors PD98059 or
U0126 in the absence or presence of SB202190. PD98059 and U0126
blunted ERK and RSK activation, enhanced TSC2 phosphorylation at
S664 and S1798, and stimulated mTORC1 signaling by SB202190
(Fig. 3E). Together, these observations indicate that MK2 and ERK/RSK
mediate the negative and positive effects of SB202190 on mTORC1 sig-
naling through selective targeting of distinct TSC2 phosphorylation sites
in p38i-inhibited and -stimulated CRC cell lines.
2.4. Combining p38 and mTOR Kinase Inhibitors Overcomes Resistance to
either Drug Alone
Since mTORC1 activation correlated with p38i-mediated growth
stimulation, this raises the possibility that targetingmTORmay counter-
act this response thereby restoring anti-tumor activity. ATP-competitive
mTOR kinase inhibitors block signaling by both mTORC1 and mTORC2,
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back activation of AKT (Zhang et al., 2011). We therefore examined
BEZ-235 and OSI-027, two mTOR kinase inhibitors being tested in
human clinical trials (Bhagwat et al., 2011). BEZ-235 and OSI-027 po-
tently inhibited both mTORC1 and mTORC2, regardless whether p38i
was present (Fig. 4A). mTOR kinase inhibitors abrogated SB202190-
induced enhancement of CRC oncogenic growth as measured by SRB,
colony formation and anchorage-independent growth assays (Supple-
mentary Fig. 2, Fig. 4B and C), and they also elevated apoptotic cell
death (Fig. 4D and E).
To assess the combination of p38 andmTORkinase inhibitors in vivo,
we generated SW620 xenograft tumors in nude mice and treated the
tumor-bearing animals with a vehicle control (VC), SB202190 and
OSI-027 individually or in combination. SB202190 achieved on-target
inhibition as shown by diminished phosphorylation of MK2 and
Hsp27 (Fig. 4F). As expected, OSI-027 blocked signaling by both
mTORC1 and mTORC2 as shown by decreased phosphorylation of
S6K1 andAKT (Fig. 4F).When SB202190 andOSI-027were used in com-
bination, all three kinases, p38, mTORC1 and mTORC2 were potently
inhibited (Fig. 4F). While SB202190 alone enhanced SW620 xenograft
tumor proliferation (Ki-67) and tumor burden (Fig. 4G and H), OSI-
027 as a single agent did not have a discernible effect on SW620
tumor growth (Fig. 4G and H) (Zhang and Zheng, 2012). In sharp con-
trast, combining SB202190 and OSI-027markedly attenuated xenograft
tumor growth (Fig. 4G and H), and induced apoptosis of xenograft
tumor cells (Fig. 4I). Taken together, these data demonstrate that com-
bined use of mTOR and p38 kinase inhibitors restores anti-CRC tumor
activity where there is an intrinsic lack of response to either drug alone.
2.5. Tumor-speciﬁc PP2AC Expression Determines Differential p38-to-
mTORC1 Signaling
Protein phosphatase 2A (PP2A) is a serine/threonine proteinphospha-
tase composed of three subunits, A, B and C (Janssens and Goris, 2001). It
has been reported that p38negatively regulates ERK in a PP2A-dependent
manner in rat cardiac ventricular myocytes (Liu and Hofmann, 2004).
However, how these two kinases crosstalk has not been examined in
cancer. We investigated expression of three PP2A subunits in CRC cell
lines. Interestingly,while the level of A andB subunits of PP2Awas similar
across different CRC cell lines, there was a marked difference in levels of
the C subunit (PP2AC), which was expressed at a much lower level in
p38i-inhibited than -stimulated CRC cells (Fig. 5A). PP2AC knockdown
in HCT116 cells resulted in marked increase in activation of ERK and
RSK, and their dependent TSC2 phosphorylation events at S664 and
S1798, respectively, as well as mTORC1 activation (Fig. 5B). Activity of
ERK and RSK was no longer responsive to SB202190 treatment after
PP2AC knockdown (Fig. 5B). Remarkably, phosphorylation of S6K1 was
now inhibited by SB202190 (Fig. 5B). Interestingly, TSC2 phosphorylation
at S1254 by MK2 was signiﬁcantly increased by PP2AC knockdown,
which was inhibited by SB202190 (Fig. 5B). These observations indicate
that down-regulation of PP2AC leads to re-programming of p38-to-
mTOR signaling from p38-ERK-RSK-TSC2-mTORC1 to p38-MK2-TSC2-
mTORC1. Essentially the same results were obtained with SW620 cells
(Fig. 5C), suggesting that the PP2AC-dependent signaling reprogramming
is common phenomenon.
To explore the relationship between PP2AC expression and p38
signaling, we ectopically expressed PP2AC in RKO and SW480 cells,Fig. 1. Opposite effects of p38 targeting on growth and survival of different CRC cells and tumo
Lower panel: CRC cells were treatedwith SB202190 at 10 μMfor different times. Cell growthwa
with SB202190 10 μM for 7–10 days andmeasured for formed colonies. Lower panel shows qua
for 2–4 weeks andmeasured for anchorage-independent growth in soft agar. Lower panel show
10 μM for 72 h and analyzed for viability by Acridine Orange Staining or PARP cleavage. Lef
immunoblot analysis of PARP cleavage. E. Nude mice bearing SW480 and RKO xenograft tum
were measured (means ± s.d., n = 6). *P b 0.01 versus VC. F. Nude mice bearing HCT116 an
tumor volumes (means ± s.d., n = 6). *P b 0.01 versus VC. G. Apoptosis in xenograft tumors t
microscopic ﬁelds (400×). H. Quantiﬁcation of TUNEL staining results (means ± s.d., n = 6). *CRC cells with low endogenous PP2AC. In contrast to PP2AC knock-
down, PP2AC overexpression signiﬁcantly decreased activity of ERK
and RSK, with concomitant reduction in phosphorylation of TSC2 at
S664 and S1798 (Fig. 5D). Remarkably, SB202190 treatment now
caused activation of ERK and RSK, which was accompanied by a con-
comitant increase in TSC2 phosphorylation at S664 and S1798, and
phosphorylation of S6K and S6 (Fig. 5D). Thus, increasing the level of
PP2AC in CRC cellswith lowendogenous PP2AC leads to reprogramming
of p38-to-mTORC1 signaling fromp38-MK2-TSC2-mTORC1 to p38-ERK-
RSK-TSC2-mTORC1. Taken together, these observations demonstrate
that the level of PP2AC is a major determinant of differential p38-to-
mTORC1 signaling that can be reprogrammed by modulation of PP2AC
expression. In response to SB202190, the binding of ERK to PP2AC was
markedly decreased in HCT116 and SW620 cells, but not in SW480
andRKOcells (Fig. 5E). Thuswhen PP2AC expression is high, the binding
of ERK to PP2AC is dependent on p38, and inhibition of p38 results in
dissociation of the ERK-PP2AC complex and hence activation of ERK
kinase.
2.6. PP2AC Expression Predicts the Outcome of p38-targeted Therapy in
Patient-derived Xenografts (PDXs)
To investigate the signiﬁcance and application of these ﬁndings, we
asked if PP2AC has a similarly heterogeneous expression in primary
humanCRC tumors by immunohistochemistry (IHC) staining of primary
tumors from 75 cases of malignant inﬁltrating CRCs. Indeed, IHC scores
varied considerably, ranging from 0 to 300 (Fig. 5F and G), suggesting
that PP2AC is a potentially useful biomarker for p38i-targeted therapy.
Patient-derived xenograft (PDX) tumors are known to closely resemble
primary tumors. Their use has transformed anticancer drug research,
enabling study of therapeutic responses in a patient-relevant setting
and accelerating the process from bench to clinic (Aparicio et al.,
2015; Morton and Houghton, 2007). We developed 40 early passage
PDX CRC tumors. H&E staining showed that these PDXs displayed histo-
logical features characteristic of primary human CRCs such as complex
glandular tumor structures and tumor stroma (Fig. 6A, Supplementary
Fig. 3A and B) (Fleming et al., 2012), which were absent from xeno-
grafted cancer cell lines, indicating that the PDXs are closely related to
the primary CRCs.
We next carried out IHC staining analysis of the PDX tumors for
PP2AC expression, which show highly variable PP2AC levels in different
tumors. 9 PDX tumors (cases 1, 12, 13, 14, 17, 25, 26, 33, 34) with low
PP2AC level (H-Score b 100) and 9 PDX tumors (cases 2, 3, 8, 11, 19,
28, 30, 31, 40) with high PP2AC level (H-Score N 200) were selected
for further analysis (Fig. 6A, Supplementary Fig. 3A and B). PP2AC
expression was further veriﬁed by immunoﬂuorescence (IF) staining
(Fig. 6A and Supplementary Fig. 3C). These two groups of PDX-bearing
mice were treated with SB202190 at 5 mg/kg daily. SB202190 strongly
attenuated growth of low PP2AC-expressing PDX tumors and achieved
tumor regression in many cases (Fig. 6B and C, Supplementary Fig. 4).
In sharp contrast, SB202190 not only failed to inhibit growth of high
PP2AC-expressing PDX tumors, but also enhanced growth of these
tumors in majority of the cases (Fig. 6D and E, Supplementary Fig. 5).
The differences in antitumor response are further clearly indicated
by the T/C values, which were at or below 0 for majority of the low
PP2AC expression PDX tumor group (0, complete growth inhibition;
b0, tumor regression) (Fig. 6F). In contrast, T/C value was at or abovers. A. Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h.
smeasured by SRB assay (means± s.d. in triplet, n=3 in triplet).B. CRC cells were treated
ntiﬁcation (means± s.d., n= 3 in triplet). C. CRC cells were treatedwith SB202190 10 μM
s quantiﬁcation (means± s.d., n = 3 in triplet).D. CRC cells were treated with SB202190
t panel, quantiﬁcation of staining results (means ± s.d., n = 3 in triplet); Right panel,
ors were treated with SB202190 (5 mg/kg/day) or drug vehicle (VC). Tumor volumes
d SW620 xenograft tumors were treated with SB202190 or drug VC and measured for
reated with SB202190 or VC were analyzed by TUNEL staining. Shown are representative
P b 0.01 versus VC.
Fig. 2. Opposing effect of p38i on mTORC1 signaling in different CRCs. A. CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition
of p38 by immunoblot. B. RKO and SW620 cells were treated with SB202190 10 μM for different times and analyzed for mTORC1 signaling by immunoblot. C. Nude mice bearing
SW480 and RKO xenograft tumors were treated with SB202190 (5 mg/kg/day) or drug vehicle (VC), and analyzed for activity of mTORC1 and p38 signaling by immunoblot. Each lane
represents an individual tumor sample. D. Nude mice bearing HCT116 and SW620 xenograft tumors were similarly analyzed as in Fig. 2C. E. CRC xenograft tumors were analyzed for
P-S6 and Ki67 by IHC. Representative microscopic ﬁelds of P-S6 and Ki67 staining are shown (400×). F. CRC cells were treated with 4 μM LY2228820, 10 μM BIRB796 or 10 μM
SB202190 for 2 h and p38 and mTORC1 signaling was analyzed by immunoblot.
1948 Y. Zhang et al. / EBioMedicine 2 (2015) 1944–1956
Fig. 3. p38 targets distinct phosphorylation sites of TSC2 in different CRC cell lines.A.WT, TSC1−/− or TSC2−/−MEF cells were treatedwith 10 μMSB202190 for 2 h and analyzed for P-S6K1
and P-S6 by immunoblot.B. CRC cellswere transfectedwith twodifferent TSC1or TSC2 siRNAs, and then treatedwith 10 μMSB202190 for 2 h. TSC1, TSC2 and P-S6K1(T389)were analyzed
by immunoblot. C. CRC cells were transfected with two different TSC1 or TSC2 siRNAs, and then treated with 10 μM SB202190 for 48 h. Cell growth was measured by SRB assay
and expressed as percentage of SB202190/control (DMSO). Data represent means ± s.d. from three independent triplicate experiments. *P b 0.01 versus NC. D. Drug-sensitive
CACO2, SW480 and RKO cells, and drug-resistant HCT116, SW620 and SW1116 cells were treated with 10 μM SB202190 for 2 h and analyzed for phosphorylation of TSC2 at S664,
S1254, T1462 and S1798 by immunoblot. Boxed area highlights the different effects of SB202190 on TSC2 phosphorylation in drug-sensitive versus -resistant CRC cells. SE, short exposure,
LE, long exposure. E. HCT116 and SW620 cells were treated with 10 μM SB202190 with or without Mek inhibitors 30 μM PD98059 or 10 μM U0126 for 2 h, and then analyzed for
phosphorylation of TSC2, ERK, RSK, S6K1 and S6 by immunoblot.
1949Y. Zhang et al. / EBioMedicine 2 (2015) 1944–1956100 for the high PP2AC expression group (100, no growth inhibition;
N100, enhanced growth). SB202190 had excellent on-target inhibition
of p38 in both groups of tumors, as shown by marked decrease in
P-MK2 staining (Fig. 6G). However, it inhibited mTORC1 signaling
(P-S6) and tumor cell proliferation (Ki67) in the low PP2AC expression
group, but enhanced mTORC1 signaling and proliferation in the high
PP2AC group (Fig. 6G). Essentially the same results are obtained with
LY2228820, another p38 inhibitor (Supplementary Fig. 6). These resultsdemonstrate that in the highly patient-relevant PDX CRCs, PP2AC
expression reliably predicts the response of targeting p38 for both
mTORC1 signaling and therapeutic outcome.
3. Discussion
In this study, we found that there is considerable variability in
therapeutic response of CRCs to p38-targeted therapy. CRC tumors
1950 Y. Zhang et al. / EBioMedicine 2 (2015) 1944–1956with lowPP2AC expression are highly sensitive to p38i, which represent
an estimated 20% CRCs. In contrast, for CRCs with high PP2AC expres-
sion, p38i treatment promotes tumor growth. Thus caution must be
taken because p38 targeting in this group of patients may worsen thetherapeutic outcome. Differential programing of p38-to-mTORC1 sig-
naling underlies the sensitivity and resistance of CRCs to p38-targeted
therapy (Fig. 7). Although p38 can regulate mTORC1 activity through
two distinct signaling axes, p38-MK2-TSC2-mTORC2 plays a dominant
1951Y. Zhang et al. / EBioMedicine 2 (2015) 1944–1956role in regulating mTORC1 activity in tumors with low PP2AC expres-
sion. In this group of CRCs, p38i leads to decreased phosphorylation of
TSC2 at S1254 by MK2, inhibition of mTORC1 signaling, and inhibition
of tumor cell survival and tumor growth. It is noteworthy that p38i in-
duces extensive apoptotic cell death in the p38i-inhibited CRCs, which
correlates with tumor regression. These observations provide compel-
ling argument for initiation of biomarker-guided (PP2AC low), single
agent p38i clinical trials for treating malignant CRCs where there is an
urgent need of efﬁcacious systemic drug therapy.
In CRCs with high PP2AC expression, the signaling ﬂow from p38
to mTORC1 is mainly mediated by ERK- and RSK-dependent TSC2
phosphorylation at S664 and S1798, respectively. Treatment of these
CRCs with p38i stimulates TSC2 phosphorylation at S664 and S1798,
resulting in activation of mTORC1, and enhancement of CRC growth
and survival. Remarkably, even though these tumors do not regress
when treated with p38 and mTOR kinase inhibitors individually, they
become highly sensitive to the combination of both inhibitors, which
not only blunts tumor growth but also promotes apoptotic cell death.
This observation suggests that p38i-induced mTORC1 activation ren-
ders CRC cells addicted to the mTORC1 pathway and thus susceptible
to mTOR kinase inhibitors. Combinational therapy for this group of
CRCs can greatly expand the utility of p38 and mTOR kinase inhibitors,
neither of which has yet made meaningful impact in oncology.
These results illustrate the complexity of the tumor growth signaling
network. Distinct routing of the same two signaling endpoints can have
drastically different outcomes for targeted therapy. We demonstrate
that p38 signal transduction to mTORC1 is determined by PP2AC levels
with a strong inverse-correlation with therapeutic outcome of p38i in
a large cohort of PDXs. Thus, PP2AC can be an excellent predictive
biomarker for selecting patients for clinical trials with p38i in single
agent therapy or in combination with an mTOR kinase inhibitor. CRC
is the second leading cancer-related death in the United States. Nearly
50% CRC patients, when diagnosed, are already at the advanced meta-
static stage and suffer dismal prognosis (Fakih, 2015). In recent years,
anti-epidermal growth factor receptor (EGFR) antibodies cetuximab
and panitumumab, in conjunction with traditional chemotherapeutic
agent ﬂuorouracil (5-FU), have extended the overall survival of some
metastatic CRC patients from 12 to 24 months. Unfortunately, the
majority of late stage CRCs carry K-RAS, N-RAS, B-RAF or PIK3CAmuta-
tions that confer resistance to the anti-EGFR therapy (Misale et al.,
2014). Therefore, new systemic therapies are urgently needed. Interest-
ingly, HCT16, RKO, SW480, SW620 and SW1116 cells all carry one or
more mutations in K-RAS, B-RAF and PIK3CA. As shown here, these
CRCs have excellent responses to either p38i alone or the combination
of p38 and mTOR kinase inhibitors. It is compelling to test p38i in
clinical settings using a biomarker-guided approach, which may bring
efﬁcacious therapeutic options for these needy patients.
4. Methods
4.1. Cell Lines, Cell Culture and Chemicals
Human colorectal cancer (CRC) cell lines (CACO-2, HCT116, RKO,
SW1116, SW480 and SW620) were purchased from ATCC and cultured
according to ATCC instructions. Wild type, TSC1−/−, TSC2+/+ p53−/−,Fig. 4. Combination of p38 andmTOR kinase inhibitors overcomes resistance to each drug as a s
or 6 μMOSI027 for 2 h and analyzed for phosphorylation of S6K1 and AKT by immunoblot. B. CR
andmeasured for colony formation. C. CRC cells were treatedwith 10 μM SB202190with or wit
CRC cells were treated with 10 μMSB202190with or without mTOR kinase inhibitor 30 nM BEZ
represent means ± s.d. from three independent triplicate experiments. *P b 0.01 versus SB202
single treatment. E. CRC cells were treated with 10 μM SB202190 with or without mTOR kin
SW620 xenograft tumors were treated with SB202190 and OSI027 individually or in combinat
was analyzed by immunoblot.G.Xenograft tumorswere analyzed for P-S6 and Ki67 by IHC. Rep
SW620 xenograft tumors were treatedwith SB202190 and OSI027 individually or in combinatio
single treatment. ★P b 0.01 versus OSI027 single treatment. I. Apoptosis of SW620 xenograft t
analyzed by TUNEL staining. Representative microscopic ﬁelds are shown (400×). Data are pr
versus OSI027 single treatment.TSC2−/− p53−/− mouse embryonic ﬁbroblast (MEF) cells (Zhang
et al., 2003) were cultured in DMEM with 10% fetal bovine serum.
SB202190, LY2228820, BIRB 796, OSI027 and BEZ235 were obtained
from Selleckchem and MedChem Express; U0126 and PD98059 were
purchased fromCell Signaling Technology. EDTA-free Complete Protease
Inhibitor Cocktail and PhosSTOPwere obtained from Roche. All cell lines
have been tested to be free of mycoplasma contamination.
4.2. Experimental Animals
Housing and all procedures using BALB/c nude mice were approved
by the Institutional Animal Care and Use Committee and in accordance
with the Animals (Scientiﬁc Procedures) Act, 1986 (UK) (amended
2013). All sections of this report adhere to the ARRIVE Guidelines for
reporting animal research. All mice were housed in individually venti-
lated cages (5 per cage) under speciﬁc pathogen free (SPF) condition.
Housing was temperature-controlled, with a 12-h/12-h light/dark
cycle. Animal weights were measured every other day.
4.3. Antibodies, Western Blot and Immunoprecipitation
Antibodies are purchased from the following vendors: P-
TSC2(S1798) (sc-293149), Santa-Cruz Biotechnology; P-TSC2(S664)
(ab133465) and S6K1 (ab32529), Abcam; PP2AA (#2041), PP2AB
(#2290), PP2AC (#2059), P-S6K1(T398) (#9234), P-AKT(S473)
(#4060), AKT (#9272), P-MK2(T334) (#3007), MK2 (#3042), P-
Hsp27 (S82) (#9709), Hsp27 (#2402), P-S6(S235/236) (#4858), S6
(#2217), P-ERK(T202/Y204) (#4370), ERK (#4695), P-RSK(S380)
(#9335), RSK (#9355), P-TSC2 (S1254) (#3616), P-TSC2(T1462)
(#3617), TSC2 (#4308), mTOR (#2983), PARP (#9532), Ki67 (#9449),
and Tubulin (#3873), Cell Signaling Technology; HRP-labeled anti-
mouse and anti-rabbit secondary antibodies, Santa-Cruz Biotechnology
and Alexa Fluor 594 conjugated secondary antibody, Invitrogen.
Western blot analysis was performed as described previously (Thomas
et al., 2014). For immunoprecipitation, CRC cells were treated with
SB202190 10 μM for 2 h prior to lysis. Then cells were lysed with
NP40 lysis buffer (50 mM Tris–HCl at pH 8.0, 150 mM NaCl, 5 mM
EDTA, 0.5% NP40), and diluted lysates were applied to immunoprecipi-
tation with anti-PP2AC antibody and immunoblotting with anti- ERK
and anti-PP2AC antibody.
4.4. siRNA and Plasmids
siRNA for human PP2AC, TSC1 and TSC2 were designed and synthe-
sized by OriGene Technologies (MD, USA). To conﬁrm the target gene
knock down effect, 2–4 oligonucleotides targeting different mRNA site
were used for each gene. siRNA sequences are as follows:
TSC2-1: 5′-AUGUUCAGCAGAAUGUCCCTT.
TSC2-2: 5′-UAAACUCCGUCUGUUUACCTT.
TSC1-1: 5′-UAUUUAACAACAUCAGCCGTT.
TSC1-2: 5′-UUUAGGCUCUCAGAAAGGCTT.
PPP2AC-1: 5′-GGAUAGCAGCAAACAAUCAUUGGAG.
PPP2AC-2: 5′-UUUGUAUCUGGUGAUUUGCTT.
PPP2AC-3: 5′-AUAUCCCUCCAUCACUAGCTT.ingle agent.A. CRC cells were treatedwith 10 μMSB202190with orwithout 30 nMBEZ235
C cells were treatedwith 10 μMSB202190with or without 30 nMBEZ235 or 6 μMOSI027
hout 30 nM BEZ235 or 6 μMOSI027 andmeasured for anchorage-independent growth.D.
235 or 6 μMOSI027 for 72 h and analyzed for cell death by Acridine Orange Staining. Data
190 single treatment. #P b 0.01 versus BEZ235 single treatment.★P b 0.01 versus OSI027
ase inhibitor 30 nM BEZ235 or 6 μM OSI027 for 72 h and analyzed for PARP cleavage. F.
ion. The effect on signaling by p38 (P-MK2 and P-Hsp27) and mTOR (P-S6K1 and P-AKT)
resentativemicroscopic ﬁelds of P-S6 and Ki67 staining are shown (400×).H.Mice bearing
n. Tumor volume data are presented asmeans± s.d. (n= 10). *P b 0.01 versus SB202190
umors treated with SB202190 and OSI027 individually or in combination (as above) was
esented as means ± s.d. (n = 10). *P b 0.01 versus SB202190 single treatment. ★P b 0.01
Fig. 5. PP2AC determines differential programming of p38-to-mTORC1 signaling. A. The protein level of PP2A-A, PP2A-B and PP2A-C in different CRC cells as analyzed by immunoblot.
B. HCT116 cells were transfected with four different PP2AC siRNAs (1, 2, 3 and 4), and then treated with 10 μM SB202190 for 2 h. Phosphorylation of TSC2, S6K1, MK2, ERK and RSK
was analyzed by immunoblot. C. SW620 cells were transfected with four different PP2AC siRNAs (1, 2, 3 and 4), and then treated with 10 μM SB202190 for 2 h. Phosphorylation of
TSC2, S6K1, S6, MK2, ERK and RSKwas analyzed by immunoblot.D. RKO and SW480 cells were transfectedwith PP2AC plasmid and then treatedwith 10 μMSB202190 for 2 h. Phosphor-
ylation of TSC2, S6K1, S6,MK2, ERK and RSKwas analyzed by immunoblot. E. Effect of p38i on ERK-PP2AC interaction in sensitive and resistant CRC cells. HCT116, SW620, SW480 and RKO
cells were treatedwithout orwith 10 μMSB202190 for 2 h. Endogenous PP2ACwas immunoprecipitatedwith a PP2AC-speciﬁc antibody and analyzed for binding to ERK byWestern blot.
F. Immunohistochemistry (IHC) staining of primary human CRC tissuemicroarray. Shown are staining of tumor tissue sections (400×) representative of high PP2AC, medium PP2AC and
low PP2AC staining. G. PP2AC is differentially expressed in CRC. Scatter plot shows PP2AC staining level in individual tumor as H-score.
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1953Y. Zhang et al. / EBioMedicine 2 (2015) 1944–1956PPP2AC-4: 5′-ACCAUAUAUCGACCUAAUGGAAATG.
Control: 5′-UUCUCCGAACGUGUCACGUTT.
For siRNA transfection, CRC cells were incubated with siRNA oligo-
nucleotides and Dharmacon transfection reagents for 16 h. Cell culture
was then replenished with fresh culture medium. Cells were harvested
48 h post-transfection for immunoblot analysis. pcDNA-PP2AC plasmid
was constructed by cloning PP2AC cDNA into pcDNA2 plasmid. Plasmid
transfection was performed using Lipofectamine 2000 according to the
manufacturer's protocol. Cells stably expressing PP2CAwere selected in
G418 for 2 weeks post plasmid transfection.
4.5. Cell Growth, Colony Formation, Anchorage-independent Growth and
Apoptosis Assays
For SRB assay, cellswere seeded in 96-well plates at an initial density
of 3 × 103 cells/well. SRB assay was performed at 48 to 96 h post-
seeding according to themanufacturer's protocols. For colony formation
assay, 200 single cells were cultured in triplicates in a 12-well plate for
1–2 weeks, and stained by methylene blue. For soft agar colony forma-
tion assay, 500 cells were seeded in 0.35% Fisher lowmelt agar on a base
of 0.7% Sigma agar in a 6-well plate. Culture dishes were transferred
sequentially to a refrigerator (4 °C) for 15 min, to room temperature
for 10 min, and then to the cell culture incubator. Agar cultures were
stained with p-Iodonitroneotetrazolium violet (Sigma-Aldrich) for 2
hours, and then inspected and photographed using a MiniCount Colony
Counter (Imaging Products International). For apoptosis assay, cells
were stained with Acridine Orange (AO) and visualized using an
inverted ﬂuorescence microscope. Apoptotic cells were deﬁned as
cells showing cytoplasmic and nuclear shrinkage, and chromatin
condensation or fragmentation. Apoptotic cell death was also detected
by the PARP cleavage assay by immunoblot.
4.6. Immunohistochemistry (IHC), Immunoﬂuorescence and TUNEL Assays
Streptavidin–Biotin Complex IHC method was used to detect Ki67,
P-S6 (S235/236), P-MK2 (T334) and PP2AC. Primary antibodies were
used at a concentration of 1:50 to 1:100. IHC signals were visualized
with DAB (3,3-diaminobenzidine), using hematoxylin as a counter-
staining. For immunoﬂuorescence staining, Alexa Fluor 594 conjugated
secondary antibody was used to detect the binding of primary antibod-
ies. DAPI (4′,6-diamidino-2-phenylindole) was used to stain the nuclei.
TUNEL assay was performed for detection of apoptotic cell death in situ
according to the manufacturer's instructions (In Situ Cell Death
DetectionKit, DAB; Roche Biotechnology). Apoptotic indexwas expressed
as the percentage of TUNEL-positive nuclei/1000 cells.
4.7. Cell Line-derived Xenograft Tumors and Drug Therapy in Athymic
Nude Mice
To generate xenograft tumors from CRC cell lines, a total of 5 × 106
to 1 × 107 cells in 100 ml PBS were injected subcutaneously into
4-week-old female BALB/c nude mice. After tumors were established,
SB202190 was administered with 5 mg/kg SB202190 dissolved in
DMSO and sterile saline by daily intraperitoneal injections for 10–
12 days. For drug vehicle control, mice received daily injection of drug
carrier. At least 6 mice were included in each treatment group. Tumor
volume was measured using a Vernier caliper and calculated according
to the formula: tumor volume (mm3) = (length × width2)/2. Tumor
volume was measured every other day and is presented as means ±
s.d. At the endpoint, mice were sacriﬁced, and tumors were removed
and photographed and frozen in liquid nitrogen or ﬁxed in formalin.
Immunoblotting, IHC and TUNEL assay were performed to examine
proliferation, cell signaling and apoptosis in xenograft tumor tissues.
For evaluating combination of SB202190 and OSI027, female BALB/c
athymic nudemice (4–6weeks old)were injected subcutaneously with5 × 106 SW620 cells to establish the CRC xenograft model. After tumors
were established, mice were randomized into four groups (10 animals
per group) for 10 consecutive days of treatment: SB202190 was admin-
istered with 5 mg/kg SB202190 in DMSO and sterile saline by daily
intraperitoneal injections, a safe dose as previously described (Lau
et al., 2007); OSI-027 was administered at 10 mg/kg OSI-027 in DMSO
and sterile saline by daily intraperitoneal injections, a dose well below
previously established safe dose (Bhagwat et al., 2011); 5 mg/kg
SB202190 plus 10 mg/kg OSI-027 were administered daily in DMSO
and sterile saline by intraperitoneal injections; drug vehicle-treated
mice received daily injection of identical solution without any drug
(Wu et al., 2015; Zhang and Zheng, 2012). Tumor volume and tissue
analysis were performed similarly.
4.8. IHC Staining of Malignant Inﬁltrating CRC Tumors
75 cases of de-identiﬁed malignant inﬁltrating CRC tumors were
randomly obtained from Jan. 2013 to Jan. 2015. This study was carried
out according to the provisions of the Helsinki Declaration of 1975.
The Streptavidin–Biotin Complex (SABC)methodwas used in immuno-
histochemistry to detect PP2AC. Primary antibodies against PP2ACwere
used at a concentration of 1:300. To score a tumor cell as positive,
cytoplasmic staining was counted. For the quantitative analysis, a
Histo score (H-score) was calculated based on staining intensity and
percentage of stained cells using the Aperio ScanScope® Systems
(Vista, CA, USA). The intensity scorewas deﬁned as follows: 0, no appre-
ciable staining in cells; 1, weak staining in cells comparable to stromal
cells; 2, intermediate staining; 3, strong staining. The fraction of positive
cells was scored as 0–100%. The H-score was calculated by multiplying
the intensity score and the fraction score, producing a total range of 0
to 300. For the purpose of data analysis, if H-score is more than 200,
the tumor was classiﬁed as high PP2AC level. In contrast, if H-score is
less than 100, the tumor was classiﬁed as low PP2AC level. Slides were
examined and scored separately by two independent pathologists.
Overall, PP2AC was highly expressed in 22 out of 75 CRC cases
(29.33%), lowly expressed in 14 out of 75 cases (18.67%).
4.9. Patient Derived Xenograft (PDX) Tumors from Colorectal Cancer
Tissues and Drug Sensitivity Assay
PDX tumors were generated as described previously (Li et al., 2007;
Morton and Houghton, 2007). Brieﬂy, samples of human colorectal
adenocarcinomas were obtained within 30 min following surgical
resection according to University Institutional Review Board (IRB)-
approved protocols. Tumors were suspended in sterile RPMI 1640 and
mechanically dissociated using scissors and then minced with a sterile
scalpel blade over ice to yield 3 × 3 × 3 mm3 pieces. Non-necrotic
tumor pieces were carefully selected and washed with serum-free PBS
before implantation. Under anesthesia with Pelltobarbitalum Natricum,
a 5-mm incision was made in the skin overlying the midabdomen of 5-
week-old male BALB/c nude mice, and 2–3 tumor pieces were im-
planted together. The skin incision was closed with tissue adhesive (B.
Braun Tissue Adhesive Histoacryl). Mice were monitored weekly for
tumor growth for 16 weeks. When tumor size in the established prima-
ry tumor models (P0) reached 1500 mm3, primary tumors were har-
vested and equally cut to small fragments of 3 × 3 × 3 mm3, and
subcutaneously re-engrafted on the ﬂank of 4–6 weeks old male Balb/
c nude mice for expansion (P1). This process was repeated. Therapeutic
assays with p38 inhibitor were performed on xenografts between P2
and P4. All procedures adhere to the BRISQGuidelines for reporting pre-
clinical research andwere sterilely performed at the SPF facility. Human
tissues used in laboratory studies do not meet the deﬁnition of human
subject research per 45 CFR 46.102 since tissues were isolated from
de-identiﬁed patient CRC tumors and have no identiﬁable private
information.
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Fig. 7. A model showing differential programming of p38-to-mTORC1 signaling deter-
mines the outcome of p38-targeted therapies. It shows the primary signal transduction
ﬂow and effect of p38 inhibition on downstream effectors when PP2AC expression is
low (left) or high (right) in CRCs.
1955Y. Zhang et al. / EBioMedicine 2 (2015) 1944–1956Xenografts were allowed to grow until they reached a size of 100–
200 mm3 and then mice were randomized into two groups (6 animals
per group) for treatment. SB202190 was administered with 5 mg/kg
SB202190 or 10 mg/kg LY2228820 (Campbell et al., 2014) dissolved in
DMSO and sterile saline by daily intraperitoneal injections for 15–24 con-
secutive days. Drug vehicle-treated mice received daily injection of iden-
tical solutionwithout SB202190or LY2228820. Tumor sizewasmeasured
every 3 days by a digital caliper using the following formula: Tumor vol-
ume=(length×width2)/2. T/C value (percent ofΔT/ΔC), the read out of
tumor response to the treatment, was calculated as tumor volume
change between the ﬁnal and initial measurement date in Group SB20/
tumor volume change in Group VC. Investigators were blinded to the
case number and correspondent PP2AC level during the experiment.
4.10. Statistical Analysis
Statistical analyses were carried out using the SAS 9.13 software.
Data were expressed as means ± s.d. and were compared using one-
way analysis of variance (ANOVA) followed by Student's t tests.
Levene's Test was used to conﬁrm the equality of variances between
each data group. All statistical tests were conducted at a two-sided
signiﬁcance level of 0.05.Fig. 6. PP2AC predicts therapeutic outcome of p38i in patient-derived xenograft (PDX) CRCmo
(14, 25, 33) with low, and three representative PDX tumors (30, 31, 40) with high PP2AC expre
PDX tumors 14, 25 and 33 were treated with SB202190 or drug vehicle (VC) and measured for
PDX tumors at the end of the experiment.D. SB202190 enhances growth of PDX tumorswith hi
or drug vehicle (VC) andmeasured for tumor volume (mean± s.d., n=6). *P b 0.05, **P b 0.01
valuewas calculated for the subgroup of 9 PDX tumorswith low PP2AC expression and the subg
df = 16, p b 0.0001). G. IHC staining of P-MK2, P-S6 and Ki67 in SB202190-treated PDX tumorConﬂict of Interests
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